Jeannine McCune

Jeannine McCune, Pharm.D.

  • Professor, Department of Population Sciences

Jeannine McCune, Pharm.D.

Areas of Expertise
  • Clinical Pharmacology
  • Pharmacokinetics
  • Ancillary Biomarker Studies
  • Grant Writing & Reviewing
  • Pediatrics
  • Hematopoietic Cell Transplant
Jeannine McCune, Pharm.D., has over 20 years of clinical research experience in oncology, predominantly in special populations — specifically hematopoietic cell transplant and pediatric cancer patients. She leads a multidiscliplinary team of analytic chemists, study coordinators and data managers to successfully conduct pharmacokinetic/dynamic studies in cancer patients.
  • 2017-present, Professor, Department of Population Sciences, City of Hope
  • 2017-present, Affiliate Investigator, Clinical Research Division, Fred Hutchinson Cancer Research Center
  • 2014-present, Affiliate Professor, Department of Pharmaceutics, University of Washington (Joint Professor 2016 to 2017)
  • 2003-2017, Co-director, Pharmacokinetics Laboratory, Fred Hutchinson Cancer Research Center and University of Washington
  • 2014-2017, Full Member, Clinical Research Division and Public Health Sciences Division, Fred Hutchinson Cancer Research Center
  • 2011-2017, Professor with tenure, Department of Pharmacy, University of Washington
  • 2008-2014, Associate Member, Clinical Research Division and Public Health Sciences Division, Fred Hutchinson Cancer Research Center
  • 2006-2011, Associate Professor with tenure, Department of Pharmacy, University of Washington
  • 2009, Research Associate, Department of Pharmaceutical Sciences, State University of New York at Buffalo (sabbatical)
  • 2003- 2009, Director, Busulfan Pharmacokinetics Laboratory, Seattle Cancer Care Alliance (resigned to pursue sabbatical)
  • 1998-2008, Affiliate Investigator, Clinical Research Division, Fred Hutchinson Cancer Research Center
  • 1998-2006, Assistant Professor, Department of Pharmacy, University of Washington

Degrees

  • 1995, Pharm.D., Clinical Pharmacy, University of North Carolina, Chapel Hill, NC
  • 1993, B.S., Pharmacy, University of Pittsburgh, Pittsburgh, PA

Fellowship

  • 1996-1998, Pharmacokinetics, University of North Carolina, Chapel Hill, NC

Residency

  • 1995-1996, Hematology/Oncology, University of North Carolina, Chapel Hill, NC
The research of Jeannine McCune, Pharm.D., focuses on the clinical pharmacology of anticancer agents and immunosuppressants used to either treat or prevent cancer. Specifically, she has quantified the exposure of anti-cancer agents and immunosuppressants in hematopoietic cell transplant recipients used to treat malignant and nonmalignant conditions. She is currently developing mathematical models to identify anticancer agent plasma exposure effective at treating cancer and modeling drug doses and dosing frequencies to optimize efficacy in pediatric cancer patients. Her work also evaluates constitutional pharmacogenomics and metabolomics relevant to drug exposure and drug response.
 
She has received several major National Institutes of Health grants for personalized medicine with children and adults with cancer, and has over 130 publications in her areas of interest. She has also served as a charter member of the NIH Developmental Therapeutics Study Section (September 2009-June 2013) and is a member of Children’s Oncology Group trials.
  • Navarro SL, Randolph TW, Shireman L, Raftery MD, McCune JS. Endogenous metabolites predict IV busulfan clearance in hematopo9etic cell transplant patients. J Proteome Res 2016 Aug 5;15(8):2802-11. DOI: 10.1021/acs.jproteome.6b00370. PMID:  27350098.
  • Palmer J, McCune JS, Perales M-A, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing Busulfan-based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. *shared first authorship. Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. DOI: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29.  PMID:  27481448.
  • McDermott CL, Sandmaier BM, Storer B, Li H, Mager DE, Boeckh MJ, Bemer MJ, Knutson J, McCune JS. Non-relapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Aug;19(8):1159-66. DOI: 10.1016/j.bbmt.2013.04.026. Epub 2013 May 6. PMID: 23660171.
  • McCune JS, Batchelder A, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB. Personalized Dosing of Cyclophosphamide in the Total Body Irradiation - Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients with Hematologic Malignancy. Clin Pharmacol Ther. 2009 Jun; 85 (6): 615-622. (epub 18 March 2009) (PMC 19295506, NIHMS111512). Results summarized in Reuters Health and Medscape Oncology, July 2009.
  • McCune JS, Salinger DH, Vicini P, Phillips B, Oglesby C, Park JR. Pharmacokinetics of Cyclophosphamide and Metabolites in Children with Neuroblastoma. J Clin Pharmacol. 2009 Jan;49(1):88-102. Epub 2008 Oct 16. (Pubmed Central (PMC) 2652687, NIHMS94095)
  • Woodahl EL, Hingorani SR, Wang J, Guthrie KA, McDonald GB, Batchelder A, Li M, Schoch HG, McCune JS. Pharmacogenomic Associations in ABCB1 and CYP3A5 With Acute Kidney Injury and Chronic Kidney Disease After Myeloablative Hematopoietic Cell Transplantation, Pharmacogenomics J. 2008 Aug;8(4):248-55. Epub 2007 Aug 14.
  • 2015-present,Chemo/Dietary Prevention Study Section Oncologic Sciences
  • 2009-2013, Developmental Therapeutics Oncologic Sciences Study Section
  • 2003-present, Children’s Oncology Group
  • 1998-present, American Society of Clinical Pharmacology & Therapeutics
  • 1994-present, American College of Clinical Pharmacy
  • Fellow, American College of Clinical Pharmacy (FCCP)
Back To Top